Cetuximab: still an option in the treatment of pancreatic cancer?

Bibliography

• Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29(34):4548-54
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85
   PubMed Web of Science ®Google Scholar
• Boonstra J, Rijken P, Humbel B, The epidermal growth factor. Cell Biol Int 1995;19:413-30
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99
   PubMed Web of Science ®Google Scholar
• Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 1986;83:5141-4
   PubMed Web of Science ®Google Scholar
• Barton CM, Hall PA, Hughes CM, Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 1991;163:111-16
   PubMed Web of Science ®Google Scholar
• Arnold D, Peinert S, Voigt W, Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 2006;11:602-11
   PubMed Web of Science ®Google Scholar
• Zhang Y, Banerjee S, Wang ZW, Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of bxpc3 pancreatic cancer cells. Cancer Res 2005;65:3877-82
   PubMed Web of Science ®Google Scholar
• Ueda S, Ogata S, Tsuda H, The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004;29:e1-8
   PubMed Web of Science ®Google Scholar
• Bloomston M, Bhardwaj A, Ellison EC, Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg 2006;23:74-9
   PubMed Web of Science ®Google Scholar
• Tobita K, Kijima H, Dowaki S, Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003;11:305-9
   PubMed Web of Science ®Google Scholar
• Kwak EL, Jankowski J, Thayer SP, Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006;12(14 Pt 1):4283-7
   PubMed Web of Science ®Google Scholar
• Lee J, Jang KT, Ki CS, Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109(8):1561-9
   PubMed Web of Science ®Google Scholar
• Tzeng CW, Frolov A, Frolova N, Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 2007;141(4):464-9
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nobuta A, Tanaka J, An effect of k-ras gene mutation on epidermal growth factor receptor signal transduction in panc-1 pancreatic carcinoma cells. Int J Cancer 1996;67:264-8
   PubMed Web of Science ®Google Scholar
• Immervoll H, Hoem D, Kugarajh K, Molecular analysis of the EGFR- ras-raf pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006;448:788-96
   PubMed Web of Science ®Google Scholar
• Lee J, Jang KT, Ki CS, Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and kras mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109:1561-9
   PubMed Web of Science ®Google Scholar
• Broadbridge VT, Karapetis CS, Price TJ. Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther 2012;12(5):555-65
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22(7):1535-46
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54
   PubMed Web of Science ®Google Scholar
• Uegaki K, Nio Y, Inoue Y, Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997;17:3841-7
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Harbison MT, Davis DW, Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-48
   PubMed Web of Science ®Google Scholar
• Cohenuram M, Saif MW. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, Present and the Future. JOP J Pancreas (Online) 2007;8(1):4-15
   PubMedGoogle Scholar
• Xiong HQ, Rosenberg A, LoBuglio A, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-16
   PubMed Web of Science ®Google Scholar
• Cascinu S, Berardi R, Labianca R, Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomized, multicenter, phase II trial. Lancet Oncol 2008;9:39-44
   PubMed Web of Science ®Google Scholar
• Kullman F, Hollerbach S, Dollinger M, Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in 1st line metastatic pancreatic cancer. First results from a multicenter phase II study. Br J Cancer 2009;100(7):1032-6
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28(22):3605-10
   PubMed Web of Science ®Google Scholar
• Burtness BA, Powell M, Berlin J, Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-R). J Clin Oncol 2007;25(Suppl):abstract 4519
   Google Scholar
• Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008;5(9):521-30
   PubMedGoogle Scholar
• De Luca A, Carotenuto A, Rachiglio A, The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214(3):559-67
   PubMed Web of Science ®Google Scholar
• Kindler HL, Gangadhar T, Karrison T, Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol 2008;26(Suppl):abstract 4502
   Google Scholar
• Ko AH, Youssoufian H, Gurtler J, A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs 2012;30(4):1597-606
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72:257-66
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002;29(5 Suppl 14):31-7
   PubMed Web of Science ®Google Scholar
• Bowers G, Reardon D, Hewitt T, The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 2001;20:1388-97
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997;15:1191-7
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Bonner JA, Grizzle WE, Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002;54:1180-93
   PubMed Web of Science ®Google Scholar
• Munter M, Timke C, Abdollahi A, Final results of a phase II trial [PARC-Study ISRCTN 56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine. J Clin Oncol 2008;26(Suppl):abstract 4613
   Google Scholar
• Goldman CK, Kim J, Wong WL, Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4(1):121-33
   PubMed Web of Science ®Google Scholar
• Ravindranath N, Wion D, Brachet P, Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 2001;22:432-43
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib improves survival when added to gemcitabine in patients with advances pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-6
   PubMed Web of Science ®Google Scholar